We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Afa5.0
Afamelanotide Research
Mostly mechanism / observational
23 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Afamelanotide studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality randomised trials published 2010–2026 with a typical study size of 70 participants.
Based on 23 studies · 3 RCTs · 70 total participants
Confidence
Moderate confidence
By outcome
Photoprotection & EPP
Mostly mechanism / observational15 studies
Skin pigmentation & vitiligo
Mostly mechanism / observational10 studies
Safety & melanocytic risk
Mostly mechanism / observational7 studies
Active research area
14 studies in the last 5 years
201020182026
1Systematic Review2023
Heerfordt IM, Lerche CM, Philipsen PA, Wulf HC · Biomed Pharmacother (2023)
No plain-language summary recorded for this citation — open the paper to read its abstract.
In plain English: Moreover, to ensure benefit for patients and access to therapy after regulatory approval, it also would be important to generate data on the relative safety and efficacy as compared to afamelanotide.
Barman-Aksözen J, Granata F, Wäscher S, Falchetto R, Dechant C. · Expert opinion on pharmacotherapy (2026)
Areas covered This narrative review (using Pubmed and trial databases) aims to provide an overview of the status of development of dersimelagon and bitopertin, with a focus on the prevention of phototoxicity.
Expert opinion The currently available trial data on dersimelagon and bitopertin suggests treatment effects in EPP as compared to placebo control groups.
However, safety and efficacy of dersimelagon and bitopertin need to be further characterized.
In plain English: Bridging the gap between molecular mechanisms and therapeutic options would be a valuable reference for physicians in clinical practice.
Ju HJ, Bae JM. · Dermatology (Basel, Switzerland) (2024)
In recent years, a great advance has been made in the understanding of pathogenesis of vitiligo, and JAK inhibitors are being investigated as a new treatment.
Minimally invasive procedures such as fractional lasers or microneedling can help achieve the optimal treatment outcome when used properly.
Key messages Our review describes various treatment modalities for vitiligo based on their molecular mechanism of action.
In plain English: Systemic treatments for vitiligo have been successful in controlling lesions without notable side effects.
Jafarzadeh A, Pour Mohammad A, Khosravi M, Amiri S, Rasouli A, Keramati H, Goodarzi A. · Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) (2024)
Results In a total of 42 included studies, oral mini-pulse corticosteroid therapy (OMP) was the subject of six studies (14.2%).
Minocycline was the focus of five studies (11.9%), while methotrexate, apremilast, and tofacitinib each were examined in four studies (9.5%).
Antioxidants and Afamelanotide were the subjects of three studies each (7.1%).
In plain English: Conclusion The advent of treatment modalities like Janus kinase inhibitors, prostaglandin analogues, antioxidants, TNF-α inhibitors, targeted phototherapy, and excimer lasers has revolutionized the therapeutic possibilities, offering a ray of hope to the individuals suffering from this devastating condition.
Ismail IB, Bhat YJ, Ul Islam MS. · Dermatology practical & conceptual (2025)
Methodology This review was performed according to PRISMA (Preferred Reporting Items for Systematic Reviews and Metanalyses) guidelines.
Two independent reviewers screened titles, abstracts, and full texts to select papers dealing with vitiligo and its treatment.
In plain English: Afamelanotide, an alpha-melanocyte-stimulating hormone analogue, is currently the only approved specific treatment that increases pain-free sunlight exposure and quality of life.
Minder AE, Kluijver LG, Barman-Aksözen J, Minder EI, Langendonk JG. · Liver international : official journal of the International Association for the Study of the Liver (2025)
Because of its rarity, there is little data on the management of EPP-related liver disease.
As a first measure, any hepatotoxins should be eliminated.
Depending on the severity of the liver disease, phlebotomies, exchange transfusions and ultimately liver transplantation with subsequent haematopoietic stem cell transplantation (HSCT) are therapeutic options, whereby multidisciplinary management including porphyria experts is mandatory.
In plain English: These advances must now be widely communicated and translated into equitable access for children across Europe.
Toenne M, Schaefer T. · European journal of pediatrics (2025)
Despite characteristic features, diagnosis is often delayed due to low awareness in paediatric care.
What is New: • This mini-review proposes a practical diagnostic algorithm for paediatric primary care and highlights key clinical clues to sensitise general paediatricians to EPP.
It also reviews emerging treatment options such as afamelanotide, already approved for adults, with promising adolescent data.
In plain English: In this review we summarize the possible use of afamelanotide in dermatology, with special emphasis on EPP and encourage including afamelanotide as a treatment option in patient care.
Polańska A, Wegner J, Nutbohm P, Staubach P, Żaba R, Dańczak-Pazdrowska A, Jenerowicz D. · Postepy dermatologii i alergologii (2024)
Its main properties are related to the enhanced production of eumelanin by agonistically binding to the melanocortin-1 receptor.
Since 2016 afamelanotide has been especially applied to treat cases of erythropoietic porphyria (EPP), where painful photosensitivity has been observed since early childhood.
The positive effect of afamelanotide in EPP administered subcutaneously improved tolerance to artificial white light and increased pain-free time spent in direct sunlight.
In plain English: Sunless tanning agents offer UV-free alternatives for cosmetic pigmentation but are not without risk.
Resnick G, Khajeh-Afzaly M, Yousefian F, Raza A, Issa NT. · The Journal of clinical and aesthetic dermatology (2026)
Conclusion Sunless tanning agents offer UV-free alternatives for cosmetic pigmentation but are not without risk.
While DHA and melanotan remain the dominant agents in current use, forskolin and carotenoids offer alternative pathways for pigmentation and photoprotection.
Further clinical studies are necessary to evaluate long-term safety, efficacy across skin types, and formulation optimization.
13Observational2024
In plain English: Cholecalciferol remains essential for the treatment of vitamin D deficiency in EPP, irrespective of new treatment options like afamelanotide.
Kluijver LG, Nekouei Shahraki M, Wagenmakers MAEM, Hanssen BE, Kuerten V, Schelonke K, Homey B, Langendonk JG. · The British journal of dermatology (2024)
Previous studies have shown that 47-63% of patients with EPP suffer from vitamin D deficiency and a high prevalence of osteoporosis.
The prevalence of vitamin D deficiency and severe deficiency remained high despite afamelanotide treatment (< 50 nmol L-1 in 71.8% of patients and < 30 nmol L-1 in 48.1%, respectively).
Afamelanotide treatment alone did not lead to a significant average increase in vitamin D levels [β = 0.5, 95% confidence interval (CI) -3.2 to 4.2].
In plain English: Afamelanotide treatment was highly effective and associated with a higher QoL in EPP patients.
Homey B, Schelonke K, Schlegel CM, Bruch-Gerharz D, Weller K, Kiefer L, Stölzel U, Staubach-Renz P, Wegner J, Keller-Melchior R, Walker G, Bochno M, Bilbao P. · Photodermatology, photoimmunology & photomedicine (2025)
EPP patients reported a significant increase in QoL compared with baseline values (p < 0.0001) and 91.0% of patients who started treatment continue being treated.
The safety profile of afamelanotide in patients over 70 years of age is consistent with the overall patient population.
Conclusions Afamelanotide treatment was highly effective and associated with a higher QoL in EPP patients.
In plain English: None of the systemic monotherapies was superior to their corresponding comparator.
Maverakis Ramirez N, Jaeger ZJ, Lee DJ. · Cureus (2026)
We further narrowed our focus to studies that could be aggregated into the intervention categories: phototherapy and systemic combination therapy (n=10), topical and topical combination therapy (n=15), and systemic monotherapy (n=5).
Treated versus control subjects showed statistically improved VASI after the following interventions were added to phototherapy: oral psoralen, oral minipulsed prednisone, implanted afamelanotide, topical ethyl vanillate, topical bimatoprost, and oral vitamins A and E.
Effective topical therapies were ruxolitinib, calcipotriol and betamethasone, tacrolimus and mometasone, and microdermabrasion and tacrolimus.
In plain English: In the phase III trial, CUV039, afamelanotide treatment improved light tolerance in patients with EPP... enabled patients to spend more time in direct sunlight without pain.
Kim ES, Garnock-Jones KP. · Am J Clin Dermatol (2016)
Drug review summarizing the approved 16 mg controlled-release subcutaneous implant for EPP
Confirmatory Phase 3 trial CUV039 increased pain-free sun-exposure time and time to first phototoxicity symptoms vs placebo
Generally well tolerated; no drug-related serious adverse events; common reactions headache and implant-site reactions
In plain English: Afamelanotide binds to the melanocortin-1 receptor (MC1R), and MC1R signaling increases melanin synthesis, induces antioxidant activities, enhances DNA repair processes and modulates inflammation.
Minder EI, Barman-Aksoezen J, Schneider-Yin X. · Clin Pharmacokinet (2017)
Pharmacokinetic/pharmacodynamic review of the first α-MSH analogue and MC1R agonist
Subcutaneous route had full bioavailability; oral and transdermal produced no measurable levels or pigmentation
Controlled-release implant is effective at lower dose than daily injections; approved by EMA in 2014 for EPP phototoxicity
In plain English: The trial results were significant, although the effects were not very large in absolute terms, and the risk-safety profile is favorable today.
Minder EI, Schneider-Yin X. · Expert Rev Clin Pharmacol (2015)
Review of the rationale and Phase II/III results of afamelanotide (CUV1647) in protoporphyria
Trial results were statistically significant though absolute effects were modest
High compliance and consistent effectiveness across six years of compassionate-use in Switzerland
In plain English: Increasing numbers of case reports indicate that the unregulated use of both melanotan I and II is associated with cutaneous complications, particularly melanocytic changes in existing moles and newly emerging (dysplastic) nevi.
Habbema L, Halk AB, Neumann M, Bergman W. · Int J Dermatol (2017)
Review of risks of unregulated α-MSH analogues (melanotan I and II) used for tanning
Contrasts these with afamelanotide, the only α-MSH analogue approved for limited medical indications and 'thoroughly tested and deemed safe'
Case reports link unregulated melanotan to melanocytic changes in moles and new dysplastic nevi; four reports describe melanomas emerging from existing moles